CHO Cell Line Development

Rapid and High-Yield IND-Ready cell line development for clinical applications.

In today’s fast-paced biotech landscape, achieving rapid and high-yield production of therapeutic proteins is crucial. CHOExpress® leverages over 20 years of expertise to offer industry-leading CHO cell lines and scalable manufacturing solutions. 

WHY CHOOSE OUR CHOEXPRESS®

Our approach ensures that you can meet your production goals efficiently and effectively, addressing the growing demand for biologics.

Benefits of using ExcellGene’s CHOExpress®

Speed

From DNA to stable clone in just 8 weeks, CHOExpress® ensures rapid development timelines to keep your projects on track.​

Scalability

Scale up to 5,000 liters without any loss in productivity, making it easier to meet commercial manufacturing demands​.

High Titers

Achieve titers over 14 g/L with fully chemically defined media, ensuring consistent and high-quality production.​
​

Clone Stability

Over 95% (or 98%) of our clones are stable, guaranteeing reliable and long-term production capabilities.​​

Flexibility

Choose from a variety of media and feeds, with licensing options available to suit your specific needs.​
​

Versatile Production

Our platform supports the production of monoclonal antibodies, bispecifics, fusion proteins, biosimilars, and virus surface proteins, catering to a wide range of therapeutic needs.

Comprehensive support

We offer end-to-end support, from gene integration to filing of the MAA/BLA  including process development and optimization, and assay development.​

HOW WE CAN HELP

Our CHOExpress® platform is designed to handle a variety of production needs.

  • Innovative products: Our fast-track program gives you the competitive edge over your competitors.
    ​
  • Bispecifics and multispecifics: Our fine-tuned chain ratios coupled with efficient integration and meticulous clone selection process for optimal protein quality and titer.
    ​
  • Biosimilars: Benefit from our high-yielding clones and scalable production capabilities for cost-effective solutions.
    ​
  • Difficult to express proteins: We offer CRISPR-like genome engineering to reach commercially viable titers and/or protein quality.